{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T00:10:20Z","timestamp":1776298220542,"version":"3.50.1"},"reference-count":9,"publisher":"American Society of Hematology","issue":"7","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,2,13]]},"abstract":"<jats:sec>\n                  <jats:title\/>\n                  <jats:p>Mantle cell lymphoma (MCL) is a rare and aggressive form of non-Hodgkin B-cell lymphoma that defies cures in most patients. Over the last decade, significant advances have been made in our understanding of the biology of the disease, patient risk stratification, and novel therapies. Associate Editor Philippe Armand presents a series of reviews that provide advice on management of patients, illuminate current understanding of the molecular landscape associated with the disease, and how that may shape future research and care. Ryan et al review the current frontline management of MCL in a rapidly evolving field, underscoring ongoing phase 3 trials; Silkenstedt and Dreyling highlight the emerging treatments for relapsed and refractory MCL; Jain and Wang tackle the critical issue of risk assignment based on clinical and molecular features; and Sarkozy and colleagues explore in depth the biology of MCL with an emphasis not only on intrinsic vulnerabilities but also on the tumor microenvironment.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1182\/blood.2024027684","type":"journal-article","created":{"date-parts":[[2025,2,13]],"date-time":"2025-02-13T16:32:59Z","timestamp":1739464379000},"page":"653-654","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":1,"title":["Introduction to a review series on mantle cell lymphoma: sands shifting in the darkness"],"prefix":"10.1182","volume":"145","author":[{"given":"Philippe","family":"Armand","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"234","reference":[{"issue":"4","key":"2025032119430168500_bib1","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1200\/JCO.2008.16.8435","article-title":"Improvement of overall survival in advanced stage mantle cell lymphoma","volume":"27","author":"Herrmann","year":"2009","journal-title":"J\u00a0Clin Oncol"},{"issue":"3","key":"2025032119430168500_bib2","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1111\/bjh.14241","article-title":"15-year follow-up of the Second Nordic Mantle Cell Lymphoma trial (MCL2): prolonged remissions without survival plateau","volume":"175","author":"Eskelund","year":"2016","journal-title":"Br J Haematol"},{"issue":"3","key":"2025032119430168500_bib3","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1200\/JCO.22.01780","article-title":"High-dose cytarabine and autologous stem-cell transplantation in mantle cell lymphoma: long-term follow-up of the Randomized Mantle Cell Lymphoma Younger Trial of the European Mantle Cell Lymphoma Network","volume":"41","author":"Hermine","year":"2023","journal-title":"J\u00a0Clin Oncol"},{"issue":"13","key":"2025032119430168500_bib4","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1056\/NEJMoa1701769","article-title":"Rituximab after autologous stem-cell transplantation in mantle-cell lymphoma","volume":"377","author":"Le Gouill","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"10441","key":"2025032119430168500_bib5","doi-asserted-by":"crossref","first-page":"2293","DOI":"10.1016\/S0140-6736(24)00184-3","article-title":"Ibrutinib combined with immunochemotherapy with or without autologous stem-cell transplantation versus immunochemotherapy and autologous stem-cell transplantation in previously untreated patients with mantle cell lymphoma (TRIANGLE): a three-arm, randomised, open-label, phase 3 superiority trial of the European Mantle Cell Lymphoma Network","volume":"403","author":"Dreyling","year":"2024","journal-title":"Lancet"},{"issue":"suppl 2","key":"2025032119430168500_bib8","article-title":"Lack of benefit of autologous hematopoietic cell transplantation (auto-HCT) in mantle cell lymphoma (MCL) patients (pts) in first complete remission (CR) with undetectable minimal residual disease (uMRD): initial report from the ECOG-ACRIN EA4151 phase 3 randomized trial [abstract]","volume":"144","author":"Fenske","year":"2024","journal-title":"Blood"},{"issue":"suppl 1","key":"2025032119430168500_bib9","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1182\/blood-2024-194641","article-title":"Addition or substitution of acalabrutinib in intensive frontline chemoimmunotherapy for patients \u226470 years old with mantle cell lymphoma: outcomes of the 3-arm randomized phase II intergroup trial ECOG-ACRIN EA4181 [abstract]","volume":"144","author":"Wagner-Johnston","year":"2024","journal-title":"Blood"},{"issue":"7","key":"2025032119430168500_bib6","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1200\/JCO.23.01586","article-title":"Long-term follow-up of rituximab maintenance in young patients with mantle-cell lymphoma included in the LYMA Trial: a LYSA Study","volume":"42","author":"Sarkozy","year":"2024","journal-title":"J\u00a0Clin Oncol"},{"issue":"5","key":"2025032119430168500_bib7","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1182\/blood.2024025563","article-title":"Zanubrutinib, obinutuzumab, and venetoclax for first-line treatment of mantle cell lymphoma with a TP53 mutation","volume":"145","author":"Kumar","year":"2025","journal-title":"Blood"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/145\/7\/653\/2355518\/blood_bld-2024-027684-c-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/145\/7\/653\/2355518\/blood_bld-2024-027684-c-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,21]],"date-time":"2025-03-21T20:01:00Z","timestamp":1742587260000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/145\/7\/653\/535441\/Introduction-to-a-review-series-on-mantle-cell"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,13]]},"references-count":9,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,2,13]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2024027684","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,13]]}}}